Bonus Biogroup Ltd

Bonus Biogroup maintains a strong liquidity position with cash and equivalents of ILS 20.45 million, which significantly exceeds its total liabilities of ILS 16.88 million, resulting in a current ratio of 2.79. The company's liquidity_fpt valuation metric indicates a low liquidity risk, supported by its cash position covering over 120% of liabilities. However, the company reported negative operating cash flow of ILS 5.08 million and free cash flow of ILS 7.41 million, indicating ongoing cash burn.

The company's profitability metrics are weak, with a return on equity of -36.06% and a return on assets of -20.4%, both significantly below the industry median for biotechnology firms. These figures suggest the company is not generating returns for shareholders or effectively utilizing its assets. The debt-to-equity ratio of 0.49 indicates a relatively conservative capital structure, with long-term debt of ILS 10.88 million compared to equity of ILS 21.98 million.

Bonus Biogroup does not disclose segment or geographic revenue breakdowns in its latest filings, making it difficult to assess revenue concentration or geographic exposure. The absence of segment data limits the ability to evaluate the performance of different product lines or regions.

The company's growth trajectory is constrained by its current financial position. With a net loss of ILS 7.92 million and operating loss of ILS 8.23 million, the company is not currently generating positive earnings. The outlook for the current fiscal year does not indicate a material improvement in revenue or profitability, with no disclosed growth initiatives or product launches expected to drive near-term revenue growth.

Risk factors include the company's ongoing losses and negative cash flows, which could pressure liquidity if cash burn continues at current rates. The risk assessment indicates low dilution risk, with no immediate filing-based flags for dilution, and shares outstanding remain unchanged between basic and diluted shares. However, the company's reliance on cash reserves to fund operations increases exposure to liquidity risk if financing is not secured.

Recent events include the latest financial filing, which shows continued losses and negative cash flows. No material events such as product approvals, partnerships, or financing rounds were disclosed in the latest available data. The absence of recent positive developments suggests the company is in a development or early commercialization phase.